Sichenzia Ross Ference Kesner LLP Represents MabVax Therapeutics Holdings, Inc. in $5 Million Registered Direct Offerings
Press Release – New York, NY – November 15, 2017 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, in a series of registered direct offerings of common stock and preferred stock for aggregate gross proceeds of approximately $5,000,000.
The offerings were consummated in August, September and October 2017. The Sichenzia Ross Ference Kesner LLP team was led by partners Harvey Kesner, Avital Perlman and Tara Guarneri-Ferrara and associate Evan Berger.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- 加州新商业融资披露立法 - September 28, 2018
- Sichenzia Ross Ference LLP宣布推出新的Web域名 - September 26, 2018
- Sichenzia Ross Ference LLP Represents AIT Therapeutics, Inc. in $20,000,000 Line of Credit - September 6, 2018